Retatrutide: A Research Reference Guide to the Triple Agonist Peptide
By Lemon Labs Research Desk · Updated June 29, 2026
In short
Retatrutide is a synthetic peptide studied as a triple agonist — it engages the GIP receptor, the GLP-1 receptor, and the glucagon receptor simultaneously. This three-receptor activity is the reason it is studied separately from single- and dual-agonist incretin peptides. It is research-use-only.
The triple-agonist concept
Where semaglutide targets one incretin receptor and tirzepatide targets two, retatrutide is engineered to engage three: GIP, GLP-1, and glucagon receptors. Adding glucagon-receptor activity to incretin agonism is the novel mechanistic element researchers investigate, since glucagon signaling influences energy expenditure pathways in research models.
Why it draws research interest
Retatrutide has become one of the most searched investigational metabolic peptides, reflecting intense interest in multi-receptor agonism. For laboratories, that interest translates into demand for well-characterized reference material to support receptor-pharmacology and signaling studies.
Handling and quality
Supplied lyophilized; store cold and sealed, protected from light. Reconstitute in the lab and verify ≥99% purity by HPLC plus mass-spec identity on the lot-specific COA.
Research-use-only statement
This compound is supplied strictly for in-vitro research and laboratory use. It is not a drug, supplement, food, or cosmetic, has not been evaluated by the FDA, and is not intended to diagnose, treat, cure, or prevent any disease. It is not for human or veterinary use. All information here summarizes published scientific literature for educational purposes for qualified researchers — it is not medical advice and does not describe human administration.
Reference compounds mentioned
Frequently asked
What does retatrutide target?
Retatrutide is studied as a triple agonist of the GIP, GLP-1, and glucagon receptors — its simultaneous three-receptor activity distinguishes it from single- and dual-agonist peptides.
How is retatrutide different from tirzepatide?
Tirzepatide is a dual GIP/GLP-1 agonist; retatrutide adds glucagon-receptor agonism, making it a triple agonist. Researchers study how the added glucagon activity changes signaling.
Is retatrutide an approved product?
No. Retatrutide is investigational, and material sold here is a research-use-only reference compound — not for human or veterinary use.